Index RUT P/E - EPS (ttm) -2.24 Insider Own 29.19% Shs Outstand 50.14M Perf Week 12.01%
Market Cap 417.93M Forward P/E - EPS next Y -1.83 Insider Trans -3.08% Shs Float 43.46M Perf Month 4.29%
Income -130.41M PEG - EPS next Q -0.47 Inst Own 62.18% Short Float 7.04% Perf Quarter 87.60%
Sales 5.76M P/S 72.56 EPS this Y 27.69% Inst Trans 0.82% Short Ratio 12.83 Perf Half Y -10.28%
Book/sh 3.66 P/B 1.86 EPS next Y 3.77% ROA -41.88% Short Interest 3.06M Perf Year 13.88%
Cash/sh 4.27 P/C 1.59 EPS next 5Y - ROE -59.51% 52W Range 2.44 - 8.84 Perf YTD 20.53%
Dividend Est. - P/FCF - EPS past 5Y -96.71% ROI -49.11% 52W High -22.96% Beta 1.44
Dividend TTM - Quick Ratio 6.56 Sales past 5Y 0.00% Gross Margin -32.61% 52W Low 179.10% ATR (14) 0.58
Dividend Ex-Date - Current Ratio 6.56 EPS Y/Y TTM 12.96% Oper. Margin -2420.91% RSI (14) 62.19 Volatility 9.96% 11.21%
Employees 133 Debt/Eq 0.20 Sales Y/Y TTM - Profit Margin -2264.53% Recom 1.00 Target Price 13.67
Option/Short Yes / Yes LT Debt/Eq 0.18 EPS Q/Q 40.21% Payout - Rel Volume 4.76 Prev Close 6.25
Sales Surprise 255.79% EPS Surprise 17.50% Sales Q/Q - Earnings Aug 08 BMO Avg Volume 238.54K Price 6.81
SMA20 11.61% SMA50 32.62% SMA200 28.81% Trades
Volume 1,016,559 Change 8.96%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated Wedbush
Outperform
$11
Jan-03-23 Upgrade Wells Fargo
Equal Weight → Overweight
$18
Oct-13-22 Initiated UBS
Buy
$22
Aug-15-22 Initiated Jefferies
Buy
$20
Apr-28-22 Initiated Credit Suisse
Neutral
$19
Feb-10-22 Initiated Wells Fargo
Equal Weight
$19
Oct-14-21 Initiated SVB Leerink
Mkt Perform
$20
Aug-28-24 07:00AM
Aug-19-24 07:00AM
Aug-08-24 08:15AM
07:15AM
(Associated Press Finance)
07:00AM
08:36AM
Loading…
Jul-08-24 08:36AM
Jun-27-24 07:00AM
Jun-14-24 08:45AM
May-30-24 07:00AM
07:00AM
May-21-24 07:00AM
May-16-24 01:09PM
07:00AM
May-15-24 04:01PM
May-10-24 03:26PM
01:55PM
Loading…
May-09-24 01:55PM
07:21AM
(Associated Press Finance)
07:00AM
May-02-24 04:01PM
Apr-29-24 10:36AM
Apr-10-24 08:50AM
Apr-04-24 09:55AM
Mar-22-24 08:50AM
Mar-19-24 09:55AM
Mar-16-24 05:31AM
Mar-14-24 01:53PM
07:22AM
(Associated Press Finance)
07:00AM
Mar-11-24 07:00AM
Jan-31-24 07:00AM
09:00AM
Loading…
Jan-16-24 09:00AM
Jan-08-24 07:15AM
Jan-03-24 07:00AM
Nov-21-23 07:00AM
Nov-09-23 08:10AM
07:10AM
(Associated Press Finance)
07:00AM
Nov-07-23 10:00AM
Oct-27-23 07:00AM
Oct-26-23 04:30PM
Oct-24-23 09:35AM
Oct-17-23 08:03AM
07:00AM
07:00AM
Aug-10-23 07:27AM
(Associated Press Finance)
07:15AM
Jul-26-23 07:30AM
Jul-16-23 09:50AM
May-30-23 04:30PM
(GlobeNewswire) +5.16%
+13.19%
May-23-23 07:30AM
May-11-23 07:50AM
07:30AM
Apr-17-23 04:30PM
Mar-23-23 07:30AM
Mar-16-23 07:52AM
07:30AM
Feb-06-23 08:30AM
Feb-03-23 07:30AM
Jan-25-23 09:55AM
Jan-09-23 07:30AM
Jan-04-23 07:30AM
Nov-17-22 01:58PM
Nov-10-22 07:30AM
Nov-01-22 07:30AM
Oct-31-22 04:30PM
Oct-20-22 04:30PM
Sep-06-22 07:30AM
Aug-30-22 08:35AM
(Simply Wall St.) -10.32%
Aug-11-22 07:30AM
Jun-14-22 05:16AM
(American City Business Journals) +5.08%
May-11-22 07:30AM
Apr-08-22 01:00PM
Mar-29-22 07:30AM
Mar-23-22 11:32AM
Feb-03-22 04:30PM
Jan-25-22 07:30AM
Jan-04-22 07:30AM
Dec-02-21 07:30AM
Nov-22-21 07:30AM
Nov-10-21 07:30AM
Nov-08-21 07:00AM
(American City Business Journals)
Oct-20-21 07:30AM
Oct-07-21 09:00AM
Sep-30-21 04:30PM
Sep-24-21 08:49AM
Sep-10-21 07:30AM
Sep-08-21 07:30AM
Aug-12-21 07:30AM
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Versant Venture Capital VI, L. 10% Owner Sep 11 '24 Sale 6.00 541,897 3,251,382 6,257,218 Sep 13 06:44 PM Versant Venture Capital VI, L. 10% Owner Sep 12 '24 Sale 6.00 16,047 96,309 6,241,171 Sep 13 06:44 PM Versant Venture Capital VI, L. 10% Owner Sep 13 '24 Sale 6.16 9,269 57,100 6,231,902 Sep 13 06:44 PM Dunn Edmund Principal Accounting Officer Jul 05 '24 Sale 3.83 1,610 6,166 13,944 Jul 09 04:15 PM Dunn Edmund Principal Accounting Officer Jun 03 '24 Sale 4.04 1,207 4,876 15,554 Jun 05 04:10 PM
Index RUT P/E - EPS (ttm) -1.54 Insider Own 23.78% Shs Outstand 51.65M Perf Week -22.86%
Market Cap 269.79M Forward P/E - EPS next Y -1.52 Insider Trans -1.62% Shs Float 43.07M Perf Month -26.88%
Income -80.55M PEG - EPS next Q -0.34 Inst Own 72.13% Short Float 14.10% Perf Quarter -1.34%
Sales 0.00M P/S - EPS this Y 25.68% Inst Trans 0.09% Short Ratio 9.43 Perf Half Y -11.74%
Book/sh 1.97 P/B 2.43 EPS next Y -8.89% ROA -59.70% Short Interest 6.07M Perf Year 38.41%
Cash/sh 2.18 P/C 2.19 EPS next 5Y - ROE -83.38% 52W Range 1.62 - 7.66 Perf YTD 69.93%
Dividend Est. - P/FCF - EPS past 5Y -49.79% ROI -61.23% 52W High -37.66% Beta 2.49
Dividend TTM - Quick Ratio 6.87 Sales past 5Y 0.00% Gross Margin - 52W Low 194.75% ATR (14) 0.47
Dividend Ex-Date - Current Ratio 6.87 EPS Y/Y TTM 32.20% Oper. Margin 0.00% RSI (14) 38.48 Volatility 10.54% 9.16%
Employees 54 Debt/Eq 0.21 Sales Y/Y TTM - Profit Margin - Recom 1.17 Target Price 13.83
Option/Short Yes / Yes LT Debt/Eq 0.18 EPS Q/Q 31.17% Payout - Rel Volume 0.76 Prev Close 4.78
Sales Surprise - EPS Surprise 6.95% Sales Q/Q - Earnings Aug 06 BMO Avg Volume 643.56K Price 4.78
SMA20 -17.68% SMA50 -16.18% SMA200 0.16% Trades
Volume 437,121 Change -0.10%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-31-24 Initiated Raymond James
Outperform
$20
Jul-14-23 Initiated Piper Sandler
Overweight
Jun-30-23 Upgrade Stifel
Hold → Buy
$2 → $10
Jun-28-23 Upgrade H.C. Wainwright
Neutral → Buy
$11
Jun-27-23 Upgrade Wedbush
Neutral → Outperform
$10
Mar-29-22 Downgrade Wedbush
Outperform → Neutral
Mar-22-22 Downgrade H.C. Wainwright
Buy → Neutral
Sep-30-21 Initiated Stifel
Hold
$10
Jan-07-21 Initiated Wedbush
Outperform
$45
Nov-24-20 Initiated Berenberg
Buy
$58
May-04-20 Initiated H.C. Wainwright
Buy
$53
Feb-24-20 Initiated JP Morgan
Overweight
$42
Feb-24-20 Initiated Jefferies
Buy
Feb-24-20 Initiated Cowen
Outperform
Feb-24-20 Initiated Canaccord Genuity
Buy
$50
Show Previous Ratings
Sep-14-24 03:30AM
Aug-08-24 04:05PM
12:00PM
Aug-06-24 01:53PM
07:37AM
(Associated Press Finance)
07:30AM
Loading…
07:30AM
Jun-29-24 08:28PM
06:30PM
Jun-01-24 10:00AM
May-29-24 08:00AM
May-16-24 08:23AM
May-10-24 08:46AM
May-09-24 01:54PM
07:30AM
07:28AM
(Associated Press Finance)
08:50AM
Loading…
Apr-29-24 08:50AM
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
Apr-08-24 09:55AM
Apr-07-24 06:00PM
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
(Associated Press Finance) -5.50%
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
08:00AM
Loading…
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
(Associated Press Finance)
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
(American City Business Journals)
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
(Associated Press Finance)
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 04:30PM
May-11-22 04:30PM
Apr-28-22 12:52PM
(American City Business Journals)
Apr-25-22 09:00AM
Apr-18-22 07:00AM
Apr-07-22 04:30PM
07:00AM
Mar-17-22 05:00PM
Mar-02-22 08:00AM
Feb-22-22 08:00AM
Feb-16-22 05:28AM
Jan-11-22 07:00AM
Jan-10-22 07:00AM
Jan-05-22 08:00AM
Nov-18-21 05:27AM
Nov-08-21 04:05PM
07:45AM
Oct-08-21 04:05PM
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Versant Venture Capital VI, L. 10% Owner Aug 28 '24 Sale 6.32 221,600 1,400,556 3,726,341 Aug 30 04:16 PM David Epstein Former Employer Jul 31 '24 Proposed Sale 6.20 50,000 310,000 Jul 31 04:18 PM David Epstein Former Employee Jul 26 '24 Proposed Sale 6.20 50,000 310,000 Jul 26 05:54 PM BIOTECH GROWTH N V 10% Owner Oct 17 '23 Buy 2.34 400,000 934,080 8,517,839 Oct 19 03:08 PM
Index - P/E - EPS (ttm) -1.61 Insider Own 15.95% Shs Outstand 22.05M Perf Week -3.79%
Market Cap 35.17M Forward P/E - EPS next Y -1.39 Insider Trans -15.56% Shs Float 21.19M Perf Month -5.74%
Income -31.75M PEG - EPS next Q -0.33 Inst Own 6.81% Short Float 9.68% Perf Quarter -31.28%
Sales 0.00M P/S - EPS this Y 25.24% Inst Trans -0.18% Short Ratio 0.70 Perf Half Y -60.26%
Book/sh 0.69 P/B 2.02 EPS next Y 2.94% ROA -87.09% Short Interest 2.05M Perf Year 185.28%
Cash/sh 1.23 P/C 1.13 EPS next 5Y - ROE -289.26% 52W Range 0.17 - 9.77 Perf YTD -68.30%
Dividend Est. - P/FCF - EPS past 5Y 62.66% ROI -114.99% 52W High -85.72% Beta -1.84
Dividend TTM - Quick Ratio 2.17 Sales past 5Y 0.00% Gross Margin - 52W Low 720.59% ATR (14) 0.13
Dividend Ex-Date - Current Ratio 2.17 EPS Y/Y TTM 38.47% Oper. Margin 0.00% RSI (14) 48.92 Volatility 9.25% 7.54%
Employees 17 Debt/Eq 1.20 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 19.50
Option/Short Yes / Yes LT Debt/Eq 0.63 EPS Q/Q 21.04% Payout - Rel Volume 0.08 Prev Close 1.41
Sales Surprise - EPS Surprise -4.17% Sales Q/Q - Earnings Aug 08 AMC Avg Volume 2.92M Price 1.39
SMA20 3.60% SMA50 -9.13% SMA200 -54.33% Trades
Volume 202,825 Change -1.06%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-14-24 Initiated Scotiabank
Sector Outperform
$13
Feb-08-24 Initiated Jefferies
Buy
$15
Sep-18-24 08:00AM
Sep-05-24 08:00AM
Aug-23-24 04:30PM
Aug-21-24 08:00AM
Aug-15-24 08:00AM
04:56PM
Loading…
Aug-08-24 04:56PM
Jun-20-24 08:13AM
08:00AM
07:28AM
Jun-18-24 06:22PM
Jun-07-24 04:30AM
May-21-24 08:00AM
May-09-24 04:29PM
Apr-26-24 04:05PM
Apr-09-24 08:00AM
08:00AM
Loading…
Apr-04-24 08:00AM
Mar-19-24 09:53PM
04:25PM
Mar-12-24 08:00AM
Mar-05-24 04:30PM
Feb-26-24 08:00AM
Feb-02-24 04:30PM
Jan-05-24 04:05PM
Dec-01-23 04:15PM
Nov-20-23 08:00AM
Nov-08-23 05:17PM
(GlobeNewswire) -8.74%
+16.31%
Oct-12-23 08:25AM
Oct-11-23 04:29PM
(InvestorPlace) +3,972.53%
08:01AM
08:00AM
07:41AM
Loading…
07:41AM
Oct-10-23 04:05PM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-10-23 04:13PM
Jul-19-23 08:00AM
May-31-23 04:05PM
(GlobeNewswire) -5.85%
-5.88%
May-25-23 05:00PM
May-19-23 04:05PM
May-10-23 04:15PM
Apr-28-23 08:00AM
Apr-27-23 04:58PM
Apr-26-23 06:41PM
Apr-17-23 09:00AM
Mar-22-23 05:26PM
Mar-15-23 04:05PM
Mar-14-23 04:30PM
Nov-22-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Nov-02-22 08:00AM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
08:00AM
Apr-08-22 01:00PM
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Aug-09-21 08:00AM
Jul-09-21 08:00AM
Jul-01-21 04:00PM
Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Versant Venture Capital VI, L. Owner Aug 12 '24 Proposed Sale 1.10 387,999 426,993 Aug 13 08:03 AM Versant Venture Capital VI, L. 10% Owner Aug 08 '24 Sale 1.35 400,000 540,040 597,940 Aug 12 08:33 PM Versant Venture Capital VI, L. 10% Owner Aug 12 '24 Sale 1.10 387,999 426,993 209,941 Aug 12 08:33 PM Versant Venture Capital VI, L. 10% Owner Aug 08 '24 Proposed Sale 18.03 400,000 7,210,532 Aug 09 03:41 PM Brady Stephen R President and CEO Jul 03 '24 Buy 2.11 35,000 73,850 46,376 Jul 08 04:15 PM Whiting Samuel Chief Medical Officer Jul 02 '24 Buy 2.13 4,672 9,951 9,573 Jul 03 07:35 PM Trojanowski Justin Corporate Controller Jun 28 '24 Buy 2.16 7,500 16,200 22,168 Jul 02 04:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
